TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2018 DA - 2018// TI - Cancer statistics, 2018 JO - CA Cancer J Clin VL - 68 UR - https://doi.org/10.3322/caac.21442 DO - 10.3322/caac.21442 ID - Siegel2018 ER - TY - JOUR AU - Monn, M. F. AU - Tatem, A. J. AU - Cheng, L. PY - 2016 DA - 2016// TI - Prevalence and management of prostate cancer among East Asian men: current trends and future perspectives JO - Urol Oncol VL - 34 UR - https://doi.org/10.1016/j.urolonc.2015.09.003 DO - 10.1016/j.urolonc.2015.09.003 ID - Monn2016 ER - TY - JOUR AU - Feng, R. M. AU - Zong, Y. N. AU - Cao, S. M. AU - Xu, R. H. PY - 2019 DA - 2019// TI - Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? JO - Cancer Commun (Lond). VL - 39 UR - https://doi.org/10.1186/s40880-019-0368-6 DO - 10.1186/s40880-019-0368-6 ID - Feng2019 ER - TY - JOUR AU - Nuhn, P. AU - Bono, J. S. AU - Fizazi, K. AU - Freedland, S. J. AU - Grilli, M. AU - Kantoff, P. W. PY - 2018 DA - 2018// TI - Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology JO - Eur Urol VL - 75 UR - https://doi.org/10.1016/j.eururo.2018.03.028 DO - 10.1016/j.eururo.2018.03.028 ID - Nuhn2018 ER - TY - JOUR AU - Peng, S. AU - Yi, Z. AU - Liu, M. PY - 2017 DA - 2017// TI - Ailanthone: a new potential drug for castration-resistant prostate cancer JO - Chin J Cancer. VL - 36 UR - https://doi.org/10.1186/s40880-017-0194-7 DO - 10.1186/s40880-017-0194-7 ID - Peng2017 ER - TY - JOUR AU - Body, J. J. AU - Casimiro, S. AU - Costa, L. PY - 2015 DA - 2015// TI - Targeting bone metastases in prostate cancer: improving clinical outcome JO - Nat Rev Urol. VL - 12 UR - https://doi.org/10.1038/nrurol.2015.90 DO - 10.1038/nrurol.2015.90 ID - Body2015 ER - TY - JOUR AU - Norum, J. AU - Nieder, C. PY - 2017 DA - 2017// TI - Treatments for metastatic prostate cancer (mPC): a review of costing evidence JO - Pharmacoeconomics. VL - 35 UR - https://doi.org/10.1007/s40273-017-0555-8 DO - 10.1007/s40273-017-0555-8 ID - Norum2017 ER - TY - JOUR AU - Wu, J. B. AU - Yin, L. AU - Shi, C. AU - Li, Q. AU - Duan, P. AU - Huang, J. M. PY - 2017 DA - 2017// TI - MAOA-dependent activation of Shh-IL6-RANKL signaling network promotes prostate cancer metastasis by engaging tumor-stromal cell interactions JO - Cancer Cell VL - 31 UR - https://doi.org/10.1016/j.ccell.2017.02.003 DO - 10.1016/j.ccell.2017.02.003 ID - Wu2017 ER - TY - JOUR AU - Turner, C. J. AU - Edwards, C. M. PY - 2016 DA - 2016// TI - The role of the microenvironment in prostate cancer-associated bone disease JO - Curr Osteoporos Rep. VL - 14 UR - https://doi.org/10.1007/s11914-016-0323-2 DO - 10.1007/s11914-016-0323-2 ID - Turner2016 ER - TY - JOUR AU - Park, S. H. AU - Keller, E. T. AU - Shiozawa, Y. PY - 2018 DA - 2018// TI - Bone marrow microenvironment as a regulator and therapeutic target for prostate cancer bone metastasis JO - Calcif Tissue Int VL - 102 UR - https://doi.org/10.1007/s00223-017-0350-8 DO - 10.1007/s00223-017-0350-8 ID - Park2018 ER - TY - JOUR AU - Dai, J. AU - Lu, Y. AU - Roca, H. AU - Keller, J. M. AU - Zhang, J. AU - McCauley, L. K. PY - 2017 DA - 2017// TI - Immune mediators in the tumor microenvironment of prostate cancer JO - Chin J Cancer. VL - 36 UR - https://doi.org/10.1186/s40880-017-0198-3 DO - 10.1186/s40880-017-0198-3 ID - Dai2017 ER - TY - JOUR AU - Xie, H. Y. AU - Shao, Z. M. AU - Li, D. Q. PY - 2017 DA - 2017// TI - Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis JO - Chin J Cancer. VL - 36 UR - https://doi.org/10.1186/s40880-017-0202-y DO - 10.1186/s40880-017-0202-y ID - Xie2017 ER - TY - JOUR AU - Croucher, P. I. AU - McDonald, M. M. AU - Martin, T. J. PY - 2016 DA - 2016// TI - Bone metastasis: the importance of the neighbourhood JO - Nat Rev Cancer VL - 16 UR - https://doi.org/10.1038/nrc.2016.44 DO - 10.1038/nrc.2016.44 ID - Croucher2016 ER - TY - JOUR AU - Haydar, N. AU - McDonald, M. M. PY - 2018 DA - 2018// TI - Tumor cell dormancy—a hallmark of metastatic growth and disease recurrence in bone JO - Curr Mol Bio Rep. VL - 4 UR - https://doi.org/10.1007/s40610-018-0088-8 DO - 10.1007/s40610-018-0088-8 ID - Haydar2018 ER - TY - JOUR AU - Lonergan, P. E. AU - Tindall, D. J. PY - 2011 DA - 2011// TI - Androgen receptor signaling in prostate cancer development and progression JO - J Carcinog. VL - 10 UR - https://doi.org/10.4103/1477-3163.83937 DO - 10.4103/1477-3163.83937 ID - Lonergan2011 ER - TY - JOUR AU - Romanel, A. AU - Tandefelt, D. AU - Conteduca, V. AU - Jayaram, A. AU - Casiraghi, N. AU - Wetterskog, D. PY - 2015 DA - 2015// TI - Plasma AR and abiraterone-resistant prostate cancer JO - Sci Transl Med. VL - 7 UR - https://doi.org/10.1126/scitranslmed.aac9511 DO - 10.1126/scitranslmed.aac9511 ID - Romanel2015 ER - TY - JOUR AU - Antonarakis, E. S. AU - Lu, C. AU - Wang, H. AU - Luber, B. AU - Nakazawa, M. AU - Roeser, J. C. PY - 2014 DA - 2014// TI - AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1315815 DO - 10.1056/NEJMoa1315815 ID - Antonarakis2014 ER - TY - JOUR AU - Denmeade, S. R. AU - Isaacs, J. T. PY - 2002 DA - 2002// TI - A history of prostate cancer treatment JO - Nat Rev Cancer VL - 2 UR - https://doi.org/10.1038/nrc801 DO - 10.1038/nrc801 ID - Denmeade2002 ER - TY - JOUR AU - Crawford, E. D. AU - Higano, C. S. AU - Shore, N. D. AU - Hussain, M. AU - Petrylak, D. P. PY - 2015 DA - 2015// TI - Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies JO - J Urol VL - 194 UR - https://doi.org/10.1016/j.juro.2015.06.106 DO - 10.1016/j.juro.2015.06.106 ID - Crawford2015 ER - TY - JOUR AU - Watson, P. A. AU - Arora, V. K. AU - Sawyers, C. L. PY - 2015 DA - 2015// TI - Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer JO - Nat Rev Cancer VL - 15 UR - https://doi.org/10.1038/nrc4016 DO - 10.1038/nrc4016 ID - Watson2015 ER - TY - JOUR AU - Augello, M. A. AU - Den, R. B. AU - Knudsen, K. E. PY - 2014 DA - 2014// TI - AR function in promoting metastatic prostate cancer JO - Cancer Metastasis Rev VL - 33 UR - https://doi.org/10.1007/s10555-013-9471-3 DO - 10.1007/s10555-013-9471-3 ID - Augello2014 ER - TY - JOUR AU - Hörnberg, E. AU - Ylitalo, E. B. AU - Crnalic, S. AU - Antti, H. AU - Stattin, P. AU - Widmark, A. PY - 2011 DA - 2011// TI - Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival JO - PLoS ONE VL - 6 UR - https://doi.org/10.1371/journal.pone.0019059 DO - 10.1371/journal.pone.0019059 ID - Hörnberg2011 ER - TY - JOUR AU - Yin, J. AU - Liu, Y. N. AU - Tillman, H. AU - Barrett, B. AU - Hewitt, S. AU - Ylaya, K. PY - 2014 DA - 2014// TI - AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-3233 DO - 10.1158/0008-5472.CAN-13-3233 ID - Yin2014 ER - TY - JOUR AU - Ylitalo, E. B. AU - Thysell, E. AU - Jernberg, E. AU - Lundholm, M. AU - Crnalic, S. AU - Egevad, L. PY - 2017 DA - 2017// TI - Subgroups of castration-resistant prostate cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response JO - Eur Urol VL - 71 UR - https://doi.org/10.1016/j.eururo.2016.07.033 DO - 10.1016/j.eururo.2016.07.033 ID - Ylitalo2017 ER - TY - JOUR AU - Li, Z. AU - Alyamani, M. AU - Li, J. AU - Rogacki, K. AU - Abazeed, M. AU - Upadhyay, S. K. PY - 2016 DA - 2016// TI - Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy JO - Nature VL - 533 UR - https://doi.org/10.1038/nature17954 DO - 10.1038/nature17954 ID - Li2016 ER - TY - JOUR AU - Vale, C. L. AU - Burdett, S. AU - Rydzewska, L. H. M. AU - Albiges, L. AU - Clarke, N. W. AU - Fisher, D. PY - 2016 DA - 2016// TI - Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data JO - Lancet Oncol. VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00489-1 DO - 10.1016/S1470-2045(15)00489-1 ID - Vale2016 ER - TY - JOUR AU - Clarke, B. PY - 2008 DA - 2008// TI - Normal bone anatomy and physiology JO - Clin J Am Soc Nephrol VL - 3 UR - https://doi.org/10.2215/CJN.04151206 DO - 10.2215/CJN.04151206 ID - Clarke2008 ER - TY - CHAP AU - Gasser, J. A. AU - Kneissel, M. ED - Smith, S. ED - Varela, A. ED - Samadfam, R. PY - 2017 DA - 2017// TI - Bone physiology and biology BT - Bone toxicology. Molecular and integrative toxicology PB - Springer CY - New York ID - Gasser2017 ER - TY - JOUR AU - Boyle, W. J. AU - Simonet, W. S. AU - Lacey, D. L. PY - 2003 DA - 2003// TI - Osteoclast differentiation and activation JO - Nature VL - 423 UR - https://doi.org/10.1038/nature01658 DO - 10.1038/nature01658 ID - Boyle2003 ER - TY - JOUR AU - Ducy, P. AU - Schinke, T. AU - Karsenty, G. PY - 2000 DA - 2000// TI - The osteoblast: a sophisticated fibroblast under central surveillance JO - Science VL - 289 UR - https://doi.org/10.1126/science.289.5484.1501 DO - 10.1126/science.289.5484.1501 ID - Ducy2000 ER - TY - JOUR AU - Burr, D. B. PY - 2019 DA - 2019// TI - Changes in bone matrix properties with aging JO - Bone VL - 120 UR - https://doi.org/10.1016/j.bone.2018.10.010 DO - 10.1016/j.bone.2018.10.010 ID - Burr2019 ER - TY - JOUR AU - Florencio-Silva, R. AU - Sasso, G. R. AU - Sasso-Cerri, E. AU - Simões, M. J. AU - Cerri, P. S. PY - 2015 DA - 2015// TI - Biology of bone tissue: structure, function, and factors that influence bone cells JO - Biomed Res Int VL - 2015 UR - https://doi.org/10.1155/2015/421746 DO - 10.1155/2015/421746 ID - Florencio-Silva2015 ER - TY - JOUR AU - Eguchi, K. AU - Akiba, Y. AU - Akiba, N. AU - Nagasawa, M. AU - Cooper, L. F. AU - Uoshima, K. PY - 2018 DA - 2018// TI - Insulin-like growth factor binding Protein-3 suppresses osteoblast differentiation via bone morphogenetic protein-2 JO - Biochem Biophys Res Commun VL - 507 UR - https://doi.org/10.1016/j.bbrc.2018.11.065 DO - 10.1016/j.bbrc.2018.11.065 ID - Eguchi2018 ER - TY - JOUR AU - Salazar, V. S. AU - Gamer, L. W. AU - Rosen, V. PY - 2016 DA - 2016// TI - BMP signalling in skeletal development, disease and repair JO - Nat Rev Endocrinol. VL - 12 UR - https://doi.org/10.1038/nrendo.2016.12 DO - 10.1038/nrendo.2016.12 ID - Salazar2016 ER - TY - JOUR AU - Verrecchia, F. AU - Rédini, F. PY - 2018 DA - 2018// TI - Transforming growth factor-β signaling plays a pivotal role in the interplay between osteosarcoma cells and their microenvironment JO - Front Oncol. VL - 8 UR - https://doi.org/10.3389/fonc.2018.00133 DO - 10.3389/fonc.2018.00133 ID - Verrecchia2018 ER - TY - JOUR AU - Hauschka, P. AU - Mavrakos, A. AU - Iafrati, M. AU - Doleman, S. AU - Klagsbrun, M. PY - 1986 DA - 1986// TI - Growth factors in bone matrix Isolation of multiple types by affinity chromatography on heparin-Sepharose JO - J Biol Chem VL - 261 ID - Hauschka1986 ER - TY - JOUR AU - Bussard, K. M. AU - Gay, C. V. AU - Mastro, A. M. PY - 2008 DA - 2008// TI - The bone microenvironment in metastasis; what is special about bone? JO - Cancer Metastasis Rev VL - 27 UR - https://doi.org/10.1007/s10555-007-9109-4 DO - 10.1007/s10555-007-9109-4 ID - Bussard2008 ER - TY - JOUR AU - Bendinelli, P. AU - Maroni, P. AU - Matteucci, E. AU - Desiderio, M. A. PY - 2016 DA - 2016// TI - Cell and signal components of the microenvironment of bone metastasis are affected by hypoxia JO - Int J Mol Sci VL - 17 UR - https://doi.org/10.3390/ijms17050706 DO - 10.3390/ijms17050706 ID - Bendinelli2016 ER - TY - JOUR AU - Shiozawa, Y. AU - Pedersen, E. A. AU - Havens, A. M. AU - Jung, Y. AU - Mishra, A. AU - Joseph, J. PY - 2011 DA - 2011// TI - Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow JO - J Clin Invest. VL - 121 UR - https://doi.org/10.1172/JCI43414 DO - 10.1172/JCI43414 ID - Shiozawa2011 ER - TY - JOUR AU - Luo, J. AU - Ok Lee, S. AU - Liang, L. AU - Huang, C. K. AU - Li, L. AU - Wen, S. PY - 2014 DA - 2014// TI - Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling JO - Oncogene VL - 33 UR - https://doi.org/10.1038/onc.2013.233 DO - 10.1038/onc.2013.233 ID - Luo2014 ER - TY - JOUR AU - Widner, D. B. AU - Park, S. H. AU - Eber, M. R. AU - Shiozawa, Y. PY - 2018 DA - 2018// TI - Interactions between disseminated tumor cells and bone marrow stromal cells regulate tumor dormancy JO - Curr Osteoporos Rep. VL - 16 UR - https://doi.org/10.1007/s11914-018-0471-7 DO - 10.1007/s11914-018-0471-7 ID - Widner2018 ER - TY - JOUR AU - Liu, C. M. AU - Hsieh, C. L. AU - Shen, C. N. AU - Lin, C. C. AU - Shigemura, K. AU - Sung, S. Y. PY - 2016 DA - 2016// TI - Exosomes from the tumor microenvironment as reciprocal regulators that enhance prostate cancer progression JO - Int J Urol VL - 23 UR - https://doi.org/10.1111/iju.13145 DO - 10.1111/iju.13145 ID - Liu2016 ER - TY - JOUR AU - Kobayashi, A. AU - Okuda, H. AU - Xing, F. AU - Pandey, P. R. AU - Watabe, M. AU - Hirota, S. PY - 2011 DA - 2011// TI - Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone JO - J Exp Med VL - 208 UR - https://doi.org/10.1084/jem.20110840 DO - 10.1084/jem.20110840 ID - Kobayashi2011 ER - TY - JOUR AU - Li, X. AU - Yang, J. AU - Bao, M. AU - Zeng, K. AU - Fu, S. AU - Wang, C. PY - 2018 DA - 2018// TI - Wnt signaling in bone metastasis: mechanisms and therapeutic opportunities JO - Life Sci VL - 208 UR - https://doi.org/10.1016/j.lfs.2018.06.036 DO - 10.1016/j.lfs.2018.06.036 ID - Li2018 ER - TY - JOUR AU - Ren, D. AU - Dai, Y. AU - Yang, Q. AU - Zhang, X. AU - Guo, W. AU - Ye, L. PY - 2019 DA - 2019// TI - Wnt5a induces and maintains prostate cancer cells dormancy in bone JO - J Exp Med VL - 216 ID - Ren2019 ER - TY - JOUR AU - Yumoto, K. AU - Eber, M. R. AU - Wang, J. AU - Cackowski, F. C. AU - Decker, A. M. AU - Lee, E. PY - 2016 DA - 2016// TI - Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow JO - Sci Rep. VL - 6 UR - https://doi.org/10.1038/srep36520 DO - 10.1038/srep36520 ID - Yumoto2016 ER - TY - JOUR AU - Decker, A. M. AU - Jung, Y. AU - Cackowski, F. C. AU - Yumoto, K. AU - Wang, J. AU - Taichman, R. S. PY - 2017 DA - 2017// TI - Sympathetic signaling reactivates quiescent disseminated prostate cancer cells in the bone marrow JO - Mol Cancer Res VL - 15 UR - https://doi.org/10.1158/1541-7786.MCR-17-0132 DO - 10.1158/1541-7786.MCR-17-0132 ID - Decker2017 ER - TY - JOUR AU - Ruppender, N. AU - Larson, S. AU - Lakely, B. AU - Kollath, L. AU - Brown, L. AU - Coleman, I. PY - 2015 DA - 2015// JO - PLoS ONE VL - 10 UR - https://doi.org/10.1371/journal.pone.0130565 DO - 10.1371/journal.pone.0130565 ID - Ruppender2015 ER - TY - JOUR AU - Byrne, N. M. AU - Summers, M. A. AU - McDonald, M. M. PY - 2019 DA - 2019// TI - Tumor cell dormancy and reactivation in bone: skeletal biology and therapeutic opportunities JO - JBMR Plus. VL - 3 UR - https://doi.org/10.1002/jbm4.10125 DO - 10.1002/jbm4.10125 ID - Byrne2019 ER - TY - JOUR AU - Sosa, M. S. AU - Bragado, P. AU - Aguirre-Ghiso, J. A. PY - 2014 DA - 2014// TI - Mechanisms of disseminated cancer cell dormancy: an awakening field JO - Nat Rev Cancer VL - 14 UR - https://doi.org/10.1038/nrc3793 DO - 10.1038/nrc3793 ID - Sosa2014 ER - TY - JOUR AU - Aguirre-Ghiso, J. A. PY - 2007 DA - 2007// TI - Models, mechanisms and clinical evidence for cancer dormancy JO - Nat Rev Cancer VL - 7 UR - https://doi.org/10.1038/nrc2256 DO - 10.1038/nrc2256 ID - Aguirre-Ghiso2007 ER - TY - JOUR AU - Guise, T. A. AU - Mohammad, K. S. AU - Clines, G. AU - Stebbins, E. G. AU - Wong, D. H. AU - Higgins, L. S. PY - 2006 DA - 2006// TI - Basic mechanisms responsible for osteolytic and osteoblastic bone metastases JO - Clin Cancer Res VL - 12 UR - https://doi.org/10.1158/1078-0432.CCR-06-1007 DO - 10.1158/1078-0432.CCR-06-1007 ID - Guise2006 ER - TY - JOUR AU - Ono, T. AU - Nakashima, T. PY - 2018 DA - 2018// TI - Recent advances in osteoclast biology JO - Histochem Cell Biol VL - 149 UR - https://doi.org/10.1007/s00418-018-1636-2 DO - 10.1007/s00418-018-1636-2 ID - Ono2018 ER - TY - JOUR AU - Walsh, M. C. AU - Choi, Y. PY - 2014 DA - 2014// TI - Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond JO - Front Immunol. VL - 5 UR - https://doi.org/10.3389/fimmu.2014.00511 DO - 10.3389/fimmu.2014.00511 ID - Walsh2014 ER - TY - JOUR AU - Tudpor, K. AU - Eerden, B. C. AU - Jongwattanapisan, P. AU - Roelofs, J. J. AU - Leeuwen, J. P. AU - Bindels, R. J. PY - 2015 DA - 2015// TI - Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio JO - Bone VL - 72 UR - https://doi.org/10.1016/j.bone.2014.11.004 DO - 10.1016/j.bone.2014.11.004 ID - Tudpor2015 ER - TY - JOUR AU - Logothetis, C. J. AU - Lin, S. H. PY - 2005 DA - 2005// TI - Osteoblasts in prostate cancer metastasis to bone JO - Nat Rev Cancer VL - 5 UR - https://doi.org/10.1038/nrc1528 DO - 10.1038/nrc1528 ID - Logothetis2005 ER - TY - JOUR AU - Lin, S. C. AU - Yu-Lee, L. Y. AU - Lin, S. H. PY - 2018 DA - 2018// TI - Osteoblastic factors in prostate cancer bone metastasis JO - Curr Osteoporos Rep. UR - https://doi.org/10.1007/s11914-018-0480-6 DO - 10.1007/s11914-018-0480-6 ID - Lin2018 ER - TY - JOUR AU - Jin, J. K. AU - Dayyani, F. AU - Gallick, G. E. PY - 2011 DA - 2011// TI - Steps in prostate cancer progression that lead to bone metastasis JO - Int J Cancer VL - 128 UR - https://doi.org/10.1002/ijc.26024 DO - 10.1002/ijc.26024 ID - Jin2011 ER - TY - JOUR AU - Keller, E. T. AU - Brown, J. PY - 2004 DA - 2004// TI - Prostate cancer bone metastases promote both osteolytic and osteoblastic activity JO - J Cell Biochem VL - 91 UR - https://doi.org/10.1002/jcb.10662 DO - 10.1002/jcb.10662 ID - Keller2004 ER - TY - JOUR AU - Wang, G. AU - Zhao, D. AU - Spring, D. J. AU - DePinho, R. A. PY - 2018 DA - 2018// TI - Genetics and biology of prostate cancer JO - Genes Dev VL - 32 UR - https://doi.org/10.1101/gad.315739.118 DO - 10.1101/gad.315739.118 ID - Wang2018 ER - TY - JOUR AU - Käkönen, S. M. AU - Mundy, G. R. PY - 2003 DA - 2003// TI - Mechanisms of osteolytic bone metastases in breast carcinoma JO - Cancer VL - 97 UR - https://doi.org/10.1002/cncr.11132 DO - 10.1002/cncr.11132 ID - Käkönen2003 ER - TY - JOUR AU - Kolb, A. D. AU - Bussard, K. M. PY - 2019 DA - 2019// TI - The bone extracellular matrix as an ideal milieu for cancer cell metastases JO - Cancers (Basel). VL - 11 UR - https://doi.org/10.3390/cancers11071020 DO - 10.3390/cancers11071020 ID - Kolb2019 ER - TY - JOUR AU - Fournier, P. G. AU - Juárez, P. AU - Jiang, G. AU - Clines, G. A. AU - Niewolna, M. AU - Kim, H. S. PY - 2015 DA - 2015// TI - The TGF-β signaling regulator PMEPA1 suppresses prostate cancer metastases to bone JO - Cancer Cell VL - 27 UR - https://doi.org/10.1016/j.ccell.2015.04.009 DO - 10.1016/j.ccell.2015.04.009 ID - Fournier2015 ER - TY - JOUR AU - Araujo, A. AU - Cook, L. M. AU - Lynch, C. C. AU - Basanta, D. PY - 2014 DA - 2014// TI - An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-13-2652 DO - 10.1158/0008-5472.CAN-13-2652 ID - Araujo2014 ER - TY - JOUR AU - Kallio, H. M. L. AU - Hieta, R. AU - Latonen, L. AU - Brofeldt, A. AU - Annala, M. AU - Kivinummi, K. PY - 2018 DA - 2018// TI - Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases JO - Br J Cancer UR - https://doi.org/10.1038/s41416-018-0172-0 DO - 10.1038/s41416-018-0172-0 ID - Kallio2018 ER - TY - JOUR AU - Rycaj, K. AU - Tang, D. G. PY - 2017 DA - 2017// TI - Molecular determinants of prostate cancer metastasis JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.21085 DO - 10.18632/oncotarget.21085 ID - Rycaj2017 ER - TY - JOUR AU - Gupta, N. AU - Duda, D. G. PY - 2016 DA - 2016// TI - Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer JO - J Biomed Res. VL - 30 ID - Gupta2016 ER - TY - JOUR AU - Conley-LaComb, M. K. AU - Semaan, L. AU - Singareddy, R. AU - Li, Y. AU - Heath, E. I. AU - Kim, S. PY - 2016 DA - 2016// TI - Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis JO - Mol Cancer. VL - 15 UR - https://doi.org/10.1186/s12943-016-0552-0 DO - 10.1186/s12943-016-0552-0 ID - Conley-LaComb2016 ER - TY - JOUR AU - Wang, N. AU - Docherty, F. E. AU - Brown, H. K. AU - Reeves, K. J. AU - Fowles, A. C. AU - Ottewell, P. D. PY - 2014 DA - 2014// TI - Prostate cancer cells preferentially home to osteoblast-rich areas in the early stages of bone metastasis: evidence from in vivo models JO - J Bone Miner Res VL - 29 UR - https://doi.org/10.1002/jbmr.2300 DO - 10.1002/jbmr.2300 ID - Wang2014 ER - TY - JOUR AU - Gravina, G. L. AU - Mancini, A. AU - Muzi, P. AU - Ventura, L. AU - Biordi, L. AU - Ricevuto, E. PY - 2015 DA - 2015// TI - CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models JO - Prostate VL - 75 UR - https://doi.org/10.1002/pros.23007 DO - 10.1002/pros.23007 ID - Gravina2015 ER - TY - JOUR AU - Carlinfante, G. AU - Vassiliou, D. AU - Svensson, O. AU - Wendel, M. AU - Heinegård, D. AU - Andersson, G. PY - 2003 DA - 2003// TI - Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma JO - Clin Exp Metastasis VL - 20 UR - https://doi.org/10.1023/A:1025419708343 DO - 10.1023/A:1025419708343 ID - Carlinfante2003 ER - TY - JOUR AU - Labernadie, A. AU - Kato, T. AU - Brugués, A. AU - Serra-Picamal, X. AU - Derzsi, S. AU - Arwert, E. PY - 2017 DA - 2017// TI - A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion JO - Nat Cell Biol VL - 19 UR - https://doi.org/10.1038/ncb3478 DO - 10.1038/ncb3478 ID - Labernadie2017 ER - TY - JOUR AU - Wang, W. AU - Wang, L. AU - Mizokami, A. AU - Shi, J. AU - Zou, C. AU - Dai, J. PY - 2017 DA - 2017// TI - Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling JO - Chin J Cancer. VL - 36 UR - https://doi.org/10.1186/s40880-017-0203-x DO - 10.1186/s40880-017-0203-x ID - Wang2017 ER - TY - JOUR AU - Ziaee, S. AU - Chu, G. C. AU - Huang, J. M. AU - Sieh, S. AU - Chung, L. W. PY - 2015 DA - 2015// TI - Prostate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristics JO - Transl Androl Urol. VL - 4 ID - Ziaee2015 ER - TY - JOUR AU - Kan, C. AU - Vargas, G. AU - Pape, F. L. AU - Clézardin, P. PY - 2016 DA - 2016// TI - Cancer cell colonisation in the bone microenvironment JO - Int J Mol Sci VL - 17 UR - https://doi.org/10.3390/ijms17101674 DO - 10.3390/ijms17101674 ID - Kan2016 ER - TY - JOUR AU - Lawson, M. A. AU - McDonald, M. M. AU - Kovacic, N. AU - Hua Khoo, W. AU - Terry, R. L. AU - Down, J. PY - 2015 DA - 2015// TI - Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche JO - Nat Commun. VL - 6 UR - https://doi.org/10.1038/ncomms9983 DO - 10.1038/ncomms9983 ID - Lawson2015 ER - TY - JOUR AU - Delgado-Calle, J. AU - Hancock, B. AU - Likine, E. F. AU - Sato, A. Y. AU - McAndrews, K. AU - Sanudo, C. PY - 2018 DA - 2018// TI - MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production JO - FASEB J. VL - 32 UR - https://doi.org/10.1096/fj.201700919RRR DO - 10.1096/fj.201700919RRR ID - Delgado-Calle2018 ER - TY - JOUR AU - McGregor, N. E. AU - Murat, M. AU - Elango, J. AU - Poulton, I. J. AU - Walker, E. C. AU - Crimeen-Irwin, B. PY - 2019 DA - 2019// TI - IL-6 exhibits both cis- and trans-signaling in osteocytes and osteoblasts, but only trans-signaling promotes bone formation and osteoclastogenesis JO - J Biol Chem VL - 294 UR - https://doi.org/10.1074/jbc.RA119.008074 DO - 10.1074/jbc.RA119.008074 ID - McGregor2019 ER - TY - JOUR AU - Rao, S. AU - Cronin, S. J. F. AU - Sigl, V. AU - Penninger, J. M. PY - 2018 DA - 2018// TI - RANKL and RANK: from mammalian physiology to cancer treatment JO - Trends Cell Biol VL - 28 UR - https://doi.org/10.1016/j.tcb.2017.11.001 DO - 10.1016/j.tcb.2017.11.001 ID - Rao2018 ER - TY - JOUR AU - González-Suárez, E. AU - Sanz-Moreno, A. PY - 2016 DA - 2016// TI - RANK as a therapeutic target in cancer JO - FEBS J VL - 283 UR - https://doi.org/10.1111/febs.13645 DO - 10.1111/febs.13645 ID - González-Suárez2016 ER - TY - JOUR AU - Park, S. H. AU - Eber, M. R. AU - Widner, D. B. AU - Shiozawa, Y. PY - 2018 DA - 2018// TI - Role of the bone microenvironment in the development of painful complications of skeletal metastases JO - Cancers (Basel). VL - 10 UR - https://doi.org/10.3390/cancers10050141 DO - 10.3390/cancers10050141 ID - Park2018 ER - TY - JOUR AU - Guan, H. AU - Mi, B. AU - Li, Y. AU - Wu, W. AU - Tan, P. AU - Fang, Z. PY - 2015 DA - 2015// TI - Decitabine represses osteoclastogenesis through inhibition of RANK and NF-κB JO - Cell Signal VL - 27 UR - https://doi.org/10.1016/j.cellsig.2015.02.006 DO - 10.1016/j.cellsig.2015.02.006 ID - Guan2015 ER - TY - JOUR AU - Dam, P. A. AU - Verhoeven, Y. AU - Trinh, X. B. AU - Wouters, A. AU - Lardon, F. AU - Prenen, H. PY - 2019 DA - 2019// TI - RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment JO - Crit Rev Oncol Hematol VL - 133 UR - https://doi.org/10.1016/j.critrevonc.2018.10.011 DO - 10.1016/j.critrevonc.2018.10.011 ID - Dam2019 ER - TY - JOUR AU - Dougall, W. C. PY - 2012 DA - 2012// TI - Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-10-2507 DO - 10.1158/1078-0432.CCR-10-2507 ID - Dougall2012 ER - TY - JOUR AU - Deng, X. AU - He, G. AU - Liu, J. AU - Luo, F. AU - Peng, X. AU - Tang, S. PY - 2014 DA - 2014// TI - Recent advances in bone-targeted therapies of metastatic prostate cancer JO - Cancer Treat Rev VL - 40 UR - https://doi.org/10.1016/j.ctrv.2014.04.003 DO - 10.1016/j.ctrv.2014.04.003 ID - Deng2014 ER - TY - JOUR AU - Rosanò, L. AU - Bagnato, A. PY - 2016 DA - 2016// TI - Endothelin therapeutics in cancer: where are we? JO - Am J Physiol Regul Integr Comp Physiol VL - 310 UR - https://doi.org/10.1152/ajpregu.00532.2015 DO - 10.1152/ajpregu.00532.2015 ID - Rosanò2016 ER - TY - JOUR AU - Reichetzeder, C. AU - Tsuprykov, O. AU - Hocher, B. PY - 2014 DA - 2014// TI - Endothelin receptor antagonists in clinical research—lessons learned from preclinical and clinical kidney studies JO - Life Sci VL - 118 UR - https://doi.org/10.1016/j.lfs.2014.02.025 DO - 10.1016/j.lfs.2014.02.025 ID - Reichetzeder2014 ER - TY - JOUR AU - Vidak, E. AU - Javoršek, U. AU - Vizovišek, M. AU - Turk, B. PY - 2019 DA - 2019// TI - Cysteine cathepsins and their extracellular roles: shaping the microenvironment JO - Cells VL - 8 UR - https://doi.org/10.3390/cells8030264 DO - 10.3390/cells8030264 ID - Vidak2019 ER - TY - JOUR AU - Bonnet, N. AU - Brun, J. AU - Rousseau, J. C. AU - Duong, L. T. AU - Ferrari, S. L. PY - 2017 DA - 2017// TI - Cathepsin K controls cortical bone formation by degrading periostin JO - J Bone Miner Res VL - 32 UR - https://doi.org/10.1002/jbmr.3136 DO - 10.1002/jbmr.3136 ID - Bonnet2017 ER - TY - JOUR AU - Munari, E. AU - Cima, L. AU - Massari, F. AU - Bertoldo, F. AU - Porcaro, A. B. AU - Caliò, A. PY - 2017 DA - 2017// TI - Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases JO - Int J Biol Markers VL - 32 UR - https://doi.org/10.5301/jbm.5000246 DO - 10.5301/jbm.5000246 ID - Munari2017 ER - TY - JOUR AU - Drake, M. T. AU - Clarke, B. L. AU - Oursler, M. J. AU - Khosla, S. PY - 2017 DA - 2017// TI - Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned JO - Endocr Rev VL - 38 UR - https://doi.org/10.1210/er.2015-1114 DO - 10.1210/er.2015-1114 ID - Drake2017 ER - TY - JOUR AU - Verbovšek, U. AU - Noorden, C. J. AU - Lah, T. T. PY - 2015 DA - 2015// TI - Complexity of cancer protease biology: cathepsin K expression and function in cancer progression JO - Semin Cancer Biol VL - 35 UR - https://doi.org/10.1016/j.semcancer.2015.08.010 DO - 10.1016/j.semcancer.2015.08.010 ID - Verbovšek2015 ER - TY - JOUR AU - Safriadi, F. PY - 2013 DA - 2013// TI - Bone metastases and bone loss medical treatment in prostate cancer patients JO - Acta Med Indones. VL - 45 ID - Safriadi2013 ER - TY - JOUR AU - Tsuzuki, S. AU - Park, S. H. AU - Eber, M. R. AU - Peters, C. M. AU - Shiozawa, Y. PY - 2016 DA - 2016// TI - Skeletal complications in cancer patients with bone metastases JO - Int J Urol VL - 23 UR - https://doi.org/10.1111/iju.13170 DO - 10.1111/iju.13170 ID - Tsuzuki2016 ER - TY - JOUR AU - Singh, T. AU - Kaur, V. AU - Kumar, M. AU - Kaur, P. AU - Murthy, R. S. AU - Rawal, R. K. PY - 2015 DA - 2015// TI - The critical role of bisphosphonates to target bone cancer metastasis: an overview JO - J Drug Target VL - 23 UR - https://doi.org/10.3109/1061186X.2014.950668 DO - 10.3109/1061186X.2014.950668 ID - Singh2015 ER - TY - JOUR AU - Nozawa, M. AU - Inagaki, T. AU - Nagao, K. AU - Nishioka, T. AU - Komura, T. AU - Esa, A. PY - 2014 DA - 2014// TI - Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis JO - Int J Clin Oncol. VL - 19 UR - https://doi.org/10.1007/s10147-013-0604-z DO - 10.1007/s10147-013-0604-z ID - Nozawa2014 ER - TY - JOUR AU - Rodrigues, P. AU - Hering, F. O. AU - Meller, A. PY - 2011 DA - 2011// TI - Adjuvant effect of IV clodronate on the delay of bone metastasis in high-risk prostate cancer patients: a prospective study JO - Cancer Res Treat. VL - 43 UR - https://doi.org/10.4143/crt.2011.43.4.231 DO - 10.4143/crt.2011.43.4.231 ID - Rodrigues2011 ER - TY - JOUR AU - Wang, T. AU - Zhang, L. AU - Han, L. AU - Liu, X. AU - Zhang, H. AU - Zhang, J. PY - 2018 DA - 2018// TI - Clinical effect of intravenous infusion of zoledronic acid combined with oral medication of cinobufagin in the treatment of metastatic bone tumors JO - Pak J Pharm Sci. VL - 31 ID - Wang2018 ER - TY - JOUR AU - Thellenberg-Karlsson, C. AU - Nyman, C. AU - Nilsson, S. AU - Blom, R. AU - Márquez, M. AU - Castellanos, E. PY - 2016 DA - 2016// TI - Bone-targeted novel cytotoxic polybisphosphonate conjugate in castration-resistant prostate cancer: a multicenter phase 1 study JO - Anticancer Res VL - 36 UR - https://doi.org/10.21873/anticanres.11249 DO - 10.21873/anticanres.11249 ID - Thellenberg-Karlsson2016 ER - TY - JOUR AU - Smith, M. R. AU - Saad, F. AU - Coleman, R. AU - Shore, N. AU - Fizazi, K. AU - Tombal, B. PY - 2012 DA - 2012// TI - Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial JO - Lancet VL - 379 UR - https://doi.org/10.1016/S0140-6736(11)61226-9 DO - 10.1016/S0140-6736(11)61226-9 ID - Smith2012 ER - TY - JOUR AU - Saad, F. AU - Sternberg, C. N. AU - Mulders, P. F. A. AU - Niepel, D. AU - Tombal, B. F. PY - 2018 DA - 2018// TI - The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer JO - Cancer Treat Rev VL - 68 UR - https://doi.org/10.1016/j.ctrv.2018.04.014 DO - 10.1016/j.ctrv.2018.04.014 ID - Saad2018 ER - TY - JOUR AU - Sobacchi, C. AU - Menale, C. AU - Villa, A. PY - 2019 DA - 2019// TI - The RANKL-RANK axis: a bone to thymus round trip JO - Front Immunol. VL - 10 UR - https://doi.org/10.3389/fimmu.2019.00629 DO - 10.3389/fimmu.2019.00629 ID - Sobacchi2019 ER - TY - JOUR AU - Fragkoulis, C. AU - Gkialas, I. AU - Papadopoulos, G. AU - Ntoumas, K. PY - 2016 DA - 2016// TI - Current therapeutic options targeting bone metastasis in metastatic castration resistant prostate cancer JO - J BUON. VL - 21 ID - Fragkoulis2016 ER - TY - JOUR AU - Zustovich, F. AU - Pastorelli, D. PY - 2016 DA - 2016// TI - Therapeutic management of bone metastasis in prostate cancer: an update JO - Expert Rev Anticancer Ther VL - 6 ID - Zustovich2016 ER - TY - JOUR AU - Miyazawa, Y. AU - Sekine, Y. AU - Syuto, T. AU - Nomura, M. AU - Koike, H. AU - Matsui, H. PY - 2017 DA - 2017// TI - Evaluation of bone turnover/quality markers and bone mineral density in prostate cancer patients receiving androgen deprivation therapy with or without denosumab JO - Anticancer Res VL - 37 ID - Miyazawa2017 ER - TY - JOUR AU - O’Carrigan, B. AU - Wong, M. H. AU - Willson, M. L. AU - Stockler, M. R. AU - Pavlakis, N. AU - Goodwin, A. PY - 2017 DA - 2017// TI - Bisphosphonates and other bone agents for breast cancer JO - Cochrane Database Syst Rev VL - 10 ID - O’Carrigan2017 ER - TY - JOUR AU - Ye, W. L. AU - Zhao, Y. P. AU - Li, H. Q. AU - Na, R. AU - Li, F. AU - Mei, Q. B. PY - 2015 DA - 2015// TI - Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer JO - Sci Rep. VL - 5 UR - https://doi.org/10.1038/srep14614 DO - 10.1038/srep14614 ID - Ye2015 ER - TY - JOUR AU - Saracino, R. AU - Luciano, R. AU - Battafarano, G. AU - Perrotta, A. AU - Muraca, M. AU - Fattore, A. PY - 2016 DA - 2016// TI - Nanoparticles-based treatment for bone metastasis JO - Curr Drug Targets VL - 17 UR - https://doi.org/10.2174/1389450116666150427154706 DO - 10.2174/1389450116666150427154706 ID - Saracino2016 ER - TY - JOUR AU - Au, K. M. AU - Satterlee, A. AU - Min, Y. AU - Tian, X. AU - Kim, Y. S. AU - Caster, J. M. PY - 2016 DA - 2016// TI - Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: turning a bone antiresorptive agent into an anticancer therapeutic JO - Biomaterials VL - 82 UR - https://doi.org/10.1016/j.biomaterials.2015.12.018 DO - 10.1016/j.biomaterials.2015.12.018 ID - Au2016 ER - TY - JOUR AU - Lee, I. H. AU - An, S. AU - Yu, M. K. AU - Kwon, H. K. AU - Im, S. H. AU - Jon, S. PY - 2011 DA - 2011// TI - Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates JO - J Control Release VL - 155 UR - https://doi.org/10.1016/j.jconrel.2011.05.025 DO - 10.1016/j.jconrel.2011.05.025 ID - Lee2011 ER - TY - JOUR AU - Chu, W. AU - Huang, Y. AU - Yang, C. AU - Liao, Y. AU - Zhang, X. AU - Yan, M. PY - 2017 DA - 2017// TI - Calcium phosphate nanoparticles functionalized with alendronate-conjugated polyethylene glycol (PEG) for the treatment of bone metastasis JO - Int J Pharm VL - 516 UR - https://doi.org/10.1016/j.ijpharm.2016.11.051 DO - 10.1016/j.ijpharm.2016.11.051 ID - Chu2017 ER - TY - JOUR AU - Lam, M. G. AU - Klerk, J. M. AU - Rijk, P. P. AU - Zonnenberg, B. A. PY - 2007 DA - 2007// TI - Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases JO - Anticancer Agents Med Chem VL - 7 UR - https://doi.org/10.2174/187152007781058596 DO - 10.2174/187152007781058596 ID - Lam2007 ER - TY - JOUR AU - Bouman-Wammes, E. W. AU - Klerk, J. M. H. AU - Bloemendal, H. J. AU - Dodewaard-de Jong, J. M. AU - Lange, R. AU - Heine, R. PY - 2019 DA - 2019// TI - Bone-targeting radiopharmaceuticals as monotherapy or combined with chemotherapy in patients with castration-resistant prostate cancer metastatic to bone JO - Clin Genitourin Cancer. VL - 17 UR - https://doi.org/10.1016/j.clgc.2018.11.014 DO - 10.1016/j.clgc.2018.11.014 ID - Bouman-Wammes2019 ER - TY - JOUR AU - Yuan, J. AU - Liu, C. AU - Liu, X. AU - Wang, Y. AU - Kuai, D. AU - Zhang, G. PY - 2013 DA - 2013// TI - Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study JO - Clin Nucl Med VL - 38 UR - https://doi.org/10.1097/RLU.0b013e318279bf4d DO - 10.1097/RLU.0b013e318279bf4d ID - Yuan2013 ER - TY - JOUR AU - Qian, C. N. AU - Mei, Y. AU - Zhang, J. PY - 2017 DA - 2017// TI - Cancer metastasis: issues and challenges JO - Chin J Cancer. VL - 36 UR - https://doi.org/10.1186/s40880-017-0206-7 DO - 10.1186/s40880-017-0206-7 ID - Qian2017 ER - TY - JOUR AU - Zhang, J. AU - Fishman, M. N. AU - Brown, J. S. AU - Gatenby, R. A. PY - 2019 DA - 2019// TI - Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer (mCRPC): updated analysis of the adaptive abiraterone (abi) study (NCT02415621) JO - Nat Commun VL - 28 ID - Zhang2019 ER - TY - JOUR AU - Zhang, J. AU - Cunningham, J. J. AU - Brown, J. S. AU - Gatenby, R. A. PY - 2017 DA - 2017// TI - Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer JO - Nat Commun. VL - 8 UR - https://doi.org/10.1038/s41467-017-01968-5 DO - 10.1038/s41467-017-01968-5 ID - Zhang2017 ER -